ACE Report Cover
Effect of teriparatide versus alendronate or no medication on periprosethtic BMD in THA
Language
Download
Cite
+ Favorites
Language
Download
Cite
+ Favorites
AceReport Image
ARTHROPLASTY
Effect of teriparatide versus alendronate or no medication on periprosethtic BMD in THA .

Teriparatide versus alendronate for the preservation of bone mineral density after total hip arthroplasty - a randomized controlled trial

J Arthroplasty. 2016 Jan;31(1):333-8

48 patients scheduled for cementless total hip arthroplasty (THA) were randomized to be postoperatively administered either daily subcutaneous teriparatide, weekly oral alendronate, or no medication. The purpose of this study was to measure and compare periprosthetic bone mineral density, defined by Gruen Zones, between groups over 48 week follow-up. In addition, serum levels of procollagen type-1 N-terminal propeptide (P1NP) and N-terminal telopeptides of type-1 collagen (NTx) were measured and assessed during follow-up. The largest decrease in BMD in all three groups was observed in Gruen Zone 7, and the degree of this decrease was significantly smaller in both the teriparatide group and alendronate group compared to the no medication group, though the difference between the teriparatide and alendronate groups was not statistically significant.

Unlock the Full ACE Report

You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now

Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics

Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics

Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions

Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics

Or upgrade today and gain access to all OrthoEvidence
content for as little as $1.99 per week.
0 of 4 monthly FREE articles unlocked
You've reached your limit of 4 free articles views this month

Access to OrthoEvidence for as little as $1.99 per week.

Stay connected with latest evidence. Cancel at any time.
  • Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
  • Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
  • Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Upgrade
Welcome Back!
Forgot Password?
Start your FREE trial today!

Account will be affiliated with


OR
Forgot Password?

OR
Please check your email

If an account exists with the provided email address, a password reset email will be sent to you. If you don't see an email, please check your spam or junk folder.

For further assistance, contact our support team.

Translate ACE Report

OrthoEvidence utilizes a third-party translation service to make content accessible in multiple languages. Please note that while every effort is made to ensure accuracy, translations may not always be perfect.

Cite this ACE Report

OrthoEvidence. Effect of teriparatide versus alendronate or no medication on periprosethtic BMD in THA. ACE Report. 2016;5(5):21. Available from: https://myorthoevidence.com/AceReport/Show/effect-of-teriparatide-versus-alendronate-or-no-medication-on-periprosethtic-bmd-in-tha

Copy Citation
Please login to enable this feature

To access this feature, you must be logged into an active OrthoEvidence account. Please log in or create a FREE trial account.

Premium Member Feature

To access this feature, you must be logged into a premium OrthoEvidence account.

Share this ACE Report